Join the Oncology Voice Network. Join for Free
The MSL - 4 Years, 200 Episodes…What’s new, What’s not
Medical Science Liaison MSL role evolution KOL engagement pharmaceutical industry trends MSL recruitment trends

The MSL - 4 Years, 200 Episodes…What’s new, What’s not


Share This Article


Summary

In this milestone 200th episode, Tom Caravela welcomes Sarah Snyder to delve into the evolving landscape of the Medical Science Liaison (MSL) role. Sarah shares insights from her experience, reflecting on the changes in MSL roles, titles, and key opinion leader engagement over the past four years. The discussion covers technological advancements and recruitment trends, highlighting the growing importance of MSLs in the pharmaceutical industry. Despite the lack of standardization in roles, Sarah contrasts experiences in large versus small companies and offers predictions for the future of medical affairs. The episode concludes with reflections on the significance of MSLs and gratitude to listeners.

Sarah Snyder, MSL Recruiter with The Carolan Group discusses how the MSL role has changed in the past 4 years, and how it has not.

Learn more about…

👉 Changes in KOL Engagement and Access
👉 Titles, Responsibilities and Career Ladder
👉 Resources that have emerged for MSLs (including tech and tools)
👉 What changes in hiring practices have emerged
👉 The MSL job market and factors that have affected it
👉 The universal standard for MSLs

Click for Source
Medical Science Liaison, MSL role evolution, KOL engagement, pharmaceutical industry trends, MSL recruitment trends

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Press Release
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
OVN Avatar OVN Staff

Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Explore OVN